biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
11:37 A decades-old liver drug joins the world's largest Parkinson's trial✦11:37 China reins in a fast route for gene therapy trials after patient deaths✦05:39 Large trial tests whether a daily pill can slow fast-moving ALS✦05:37 More years of periods and hormone therapy tied to healthier brain vessels✦05:36 Drug-switched brain therapy tried in 3 people with hard-to-treat epilepsy✦23:40 New kind of prostate cancer drug showed promising signs, Yale team reports✦23:36 Cell therapy erased signs of hard-to-treat lymphoma in 3 of 4, maker says✦23:36 Gene fix for sickle cell freed 3 patients from transfusions, maker says✦11:37 A decades-old liver drug joins the world's largest Parkinson's trial✦11:37 China reins in a fast route for gene therapy trials after patient deaths✦05:39 Large trial tests whether a daily pill can slow fast-moving ALS✦05:37 More years of periods and hormone therapy tied to healthier brain vessels✦05:36 Drug-switched brain therapy tried in 3 people with hard-to-treat epilepsy✦23:40 New kind of prostate cancer drug showed promising signs, Yale team reports✦23:36 Cell therapy erased signs of hard-to-treat lymphoma in 3 of 4, maker says✦23:36 Gene fix for sickle cell freed 3 patients from transfusions, maker says
← People to follow
OB
PERSON TO FOLLOW

Oliver Bandmann

Professor of Movement Disorders Neurology, University of Sheffield

Bandmann is an honorary consultant neurologist at Sheffield Teaching Hospitals NHS Foundation Trust. He led the Sheffield research that identified the liver drug ursodeoxycholic acid (UDCA) as a possible way to slow Parkinson's, and co-led its early-stage UP study. He co-leads the UDCA arm of the EJS ACT-PD trial.

parkinson's diseasedrug repurposingmitochondriaclinical trials

WHAT TO WATCHProgress and eventual results of the UDCA arm of the EJS ACT-PD trial.

ON THE WIRE

Every story about Oliver’s work.

Profile sources

  1. 1
    Sheffield Drug Joins Worlds Largest Parkinsons Trial Mirage News
  2. 2
    Treatment selection and prioritization for the EJS ACT-PD MAMS trial platform Crick